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Abstract Breast cancer is a burden for western societies,
and an increasing one in emerging economies, because of its
high incidence and enormous psychological, social, sanitary
and economic costs. However, breast cancer is a prevent-
able disease in a significant proportion. Recent develop-
ments in the armamentarium of effective drugs for breast
cancer prevention (namely exemestane and anastrozole),
the new recommendation from the National Institute for
Health and Care Excellence to use preventative drugs in
women at high risk as well as updated Guidelines from the
US Preventive Services Task Force and the American
Society of Clinical Oncology should give renewed
momentum to the pharmacological prevention of breast
cancer. In this article we review recent major developments
in the field and examine their ongoing repercussion for
breast cancer prevention. As a practical example, the
potential impact of preventive measures in Spain is evalu-
ated and a course of practical actions is delineated.
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Introduction
In spite of its demonstrated efficacy, the pharmacological
prevention of breast cancer is still struggling to make a
substantial impact in terms of population uptake and public
health repercussions due to a variety of reasons, related in
part to perceived risks of severe side effects caused by
tamoxifen but also because of lack of a unequivocal
impulse and support on the part of health authorities and
breast cancer professionals and organisations. Recent sci-
entific, institutional and public awareness developments
could perhaps provide the necessary momentum to change
this scenario. From the scientific point of view there have
been two significant additions to the armamentarium of
effective drugs to prevent breast cancer in postmenopausal
women, namely exemestane and anastrozole. At the same
time, there has been a wealth of social and media reper-
cussions related to known celebrities. Institutions like
National Institute for Health and Care Excellence (NICE)
have included the recommendation for chemoprevention
for certain populations and the US Preventive Services
Task Force (USPSTF) and the American Society of Clin-
ical Oncology (ASCO) have provided updates of their
stance on Breast Cancer Prevention. Please note that we are
endorsing the use of preventive treatment instead of che-
moprevention because of the negative association of such
term with chemotherapy, not only in Spain but in most
other countries as well [1].
BRCA associated breast cancer: the Jolie effect
In chronological order, the first news to hit the headlines
with very broad circulation was the coverage of the
announcement of Angelina Jolie’s decision in May 2013 to
undergo prophylactic bilateral mastectomy [2] because she
was a carrier of a deleterious mutation in BRCA1.
Although this is a common practice among women carriers
of this condition, the way in which the news was com-
municated led some people to believe that this was a
measure that was applicable to a much wider population.
There is certainly the need for greater collaboration
between the media and the experts in order to improve how
news of this kind is presented, and also a more thorough
explanation of the context is required by the doctors. It is
also extremely important to have programmes of contin-
uing training for general practitioners and other specialists,
who are the ones to first receive requests for information
from women patients. Generally speaking, the Jolie effect
has been positive worldwide and used by doctors and
professional societies alike to reinforce messages of pre-
vention in this high risk population. A recent work by J.
Raphael et al. [3] has shown a doubling in the use of BRCA
testing in the 6 months after Jolie’s announcement.
Importantly this increase was correctly requested since the
positivity rate remained constant. Nonetheless, even when
appropriate this rise in genetic counselling and testing
conveys increased costs for Health Systems that should be
accounted for. For women carriers of a BRCA mutation,
prophylactic mastectomies can save lives not only when
performed before a cancer diagnosis but also after having
being diagnosed of a first breast tumour, as shown in new
studies [4]. That is also the case for prophylactic salpingo-
oophorectomies [5]. However, as a modelling work
recently found out, contralateral mastectomy will probably
not provide significant benefits in breast cancer women
with average risk [6]. The key message we should give to
our patients, relatives and to carriers or individuals with a
high risk of deleterious mutations in these genes, is that
knowledge of their genetic state can lead to the application
of measures that can save lives, both of subjects who have
not already had any of the associated diseases, and of
individuals who have had the early stages of one of the
primary tumour. In parallel, it is important to remember to
convey the important message that women carriers of the
BRCA mutations, who develop cancer, do not have a worse
prognosis of their disease than sporadic breast cancer [7].
Although, in the metastatic disease a cure still seems to be
out of our grasp, the new generation of clinical trials with
better-targeted treatments could create new standards with
better survivals and management of this group of diseases,
both of those linked and those not linked to BRCA.
NICE discovers chemoprevention
The second piece of news that also had an important media
impact, and its fair share of misinterpretations, was the
recommendation by the British National Institute for
Health and Care Excellence, better known as NICE, for
tamoxifen and raloxifene to be considered as agents with
positive cost-effectiveness, the use of which should be
encouraged in the National Health Service. In some cases,
the media combined this news with the previous one,
hastily concluding that tamoxifen was a new medication
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that could prevent the need for mastectomies in women
carriers of the BRCA mutation. This confusion could have
partly arisen from the fact that tamoxifen and raloxifene
were referred to in the GC164 guidelines ‘‘Familial breast
cancer: Classification and care of people at risk of familial
breast cancer and management of breast cancer and related
risks in people with a family history of breast cancer’’
published on 25th June 2013 [8]. The reference to oestro-
gen receptor antagonists is included in point 1.7 ‘‘Risk
reduction and treatment strategies’’. Although a family
history is not a mandatory criterion, the guideline does call
for the estimated risk to develop cancer from 20 years
onwards to be ‘‘moderate’’ (between 18 and 19 % in their
lifetime or from 3 to 8 % in their forties) or ‘‘high’’ (more
than 30 % total lifetime risk or higher than 8 % in their
forties) (Table 1, adapted from reference [8]).
In fact, the general recommendation is to offer tamoxi-
fen (premenopausal women), or tamoxifen or raloxifene to
postmenopausal women with a high risk (see definition in
Table 1) for 5 years, unless they have a family history of
thromboembolic disease or cancer of the uterus. This rec-
ommendation would, therefore, only hold for the group
with the least solid evidence available for prevention. It is
important to emphasize that seminal prevention studies
with tamoxifen or raloxifene [9–11] have not specifically
targeted high risk populations, but instead moderate risk
ones, being equivalent, in American trials, to the baseline
risk of breast cancer in a 60-year-old woman without any
other risk factors, corresponding to an approximate risk of
developing breast cancer in 5 years of 1.7 % [12]. In
British studies, algorithms have been used that assign more
relevance to family history [13, 14]. In any case, both
levels of risk are well below those suggested in the NICE
guidelines. Intuitively, one could say that the higher the
baseline risk of a population, the more likely that an
intervention will be successful, with a favourable cost-
effectiveness ratio. In the case of tumours linked to BRCA,
tamoxifen seems to reduce the incidence of primary or
contralateral tumour, similarly to non-genetically predis-
posed patients. However, the data available have been
obtained retrospectively with a low number of patients in
randomised trials, or correspond to non-prospective cohort
studies [15–18]. On the other hand limiting the use of
tamoxifen or other agents to these very high risk popula-
tions would limit their true preventive potential and the
possibility of obtaining benefits on a larger scale. If we
draw a parallel with the use of lipid-lowering drugs, if we
only used these medications in carriers of severe hereditary
hypercholesterolemia, we would be stripping them of their
broad preventive cardiovascular effectiveness in the gen-
eral population.
An interesting practical point is that the NICE recom-
mendation has been made in spite of the fact that neither
tamoxifen nor raloxifene are authorised for this indication
in the UK or in any other country of the European Union.
This is why the guidelines say that ‘‘the prescriber should
follow relevant professional recommendations, accepting
full responsibility for his/her decision. The patient must
provide informed consent that must be documented’’. This
context can be equated to the Spanish situation, and in our
opinion could be considered as a procedural reference.
Informed consent records are a key aspect that should be
systematically incorporated when using agents for indica-
tions that do not have the approval of the AEMPS or the
EMA.
It is worth mentioning that NICE update was preceded
by the direct recommendation by a group of experts in the
St. Gallen conference of 2010 that NICE and other gov-
ernmental and regulatory bodies use specific and differ-
entiated criteria to evaluate preventive treatments [1]. The
corollary is that the Spanish Society of Medical Oncology
(SEOM) and Breast Cancer Oriented Cooperative Groups
like the GEICAM Spanish Breast Cancer Group and others
should make their voice heard by the corresponding
authorities in the same way.
ASCO (mainly) and the US Preventive Services Task
Force (USPSTF) reinforce their message
about prevention in breast cancer
In April 2013, the USPSTF updated the recommendations
they had developed back in 2002 (11 years earlier) [19].
They acknowledge that they have taken mainly into con-
sideration the update of the STAR study data, which
showed that with an 81-month follow-up, the preventive
effectiveness of tamoxifen was greater than that of ra-
loxifene [20]. Unlike the NICE guidelines, these are more
general recommendations, only reinforcing the message for
the highest risk women, and make the assumption that
women with a history of atypical dysplasia or lobulillar
carcinoma in situ could benefit the most, based on data of
the NSABP P1 trial and another observational study
Table 1 Breast cancer risk classification
Risk similar to the
general population
Moderate risk High
riska
Lifetime risk after
20 years old
\17 % More than
17 % but
\30 %
30 % or
over
Risk between 40
and 50 years old
\3 % 3–8 % More than
8 %
a This group includes known mutations in the BRCA1, BRCA2 and
TP53 genes and other rarer diseases with a high risk of breast cancer
such as Peutz–Jegher syndrome (STK11), Cowden (PTEN) and
hereditary diffuse gastric cancer (E-cadherin)
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Table 2 Comparison of recommendations by agencies
ASCO (ref. [25]) USPTF (ref. [19]) NICE (ref. [8])
Agent
Tamoxifen Premenopausal women C35 years old
with a 5-year projected absolute BC risk
C1.66 % or with LCIS
Premenopausal women aged C35 years
who are at increased risk for breast
cancer without a prior diagnosis of
breast cancer, DCIS or LCIS
Offer to premenopausal women at high
risk of breast cancer
Consider for premenopausal women at
moderate risk of breast cancer
Postmenopausal women C35 years with a
5-year projected absolute BC risk
C1.66 % or with LCIS
Postmenopausal women aged C35 years
who are at increased risk for breast
cancer without a prior diagnosis of
breast cancer, DCIS or LCIS
Offer to postmenopausal women with or
without a uterus and at high risk of
breast cancer
Consider for postmenopausal women
with or without a uterus and at
moderate risk of breast cancer
Not recommended if history of deep vein
thrombosis, pulmonary embolus, stroke,
or transient ischemic attack or during
prolonged immobilisation
Not to be used in women with a history of
thromboembolic events (deep venous
thrombosis, pulmonary embolus, stroke,
or transient ischemic attack)
Not recommended if they have a past
history or may be at increased risk of
thromboembolic disease or
endometrial cancer or bilateral
mastectomy
Not recommended in combination with
hormone therapy
Not recommended for pregnant women,
women who may become pregnant, or
nursing mothers
Not recommended for pregnant women,
women who may become pregnant, or
nursing mothers
Raloxifene Postmenopausal women who are
C35 years old with a 5-year projected
absolute BC risk C1.66 % or with LCIS
Postmenopausal women aged C35 years
who are at increased risk for breast
cancer without a prior diagnosis of
breast cancer, DCIS or LCIS
Offer to postmenopausal women with a
uterus and at high risk of breast cancer
Consider for postmenopausal women
with a uterus and at moderate risk of
breast cancer
Should not be used for BC risk reduction
in premenopausal women
Not recommended if history of deep vein
thrombosis, pulmonary embolus, stroke,
or transient ischemic attack or during
prolonged immobilisation
Not to be used in women with a history of
thromboembolic events (deep venous
thrombosis, pulmonary embolus, stroke,
or transient ischemic attack)
Not recommended if they have a past
history or may be at increased risk of
thromboembolic disease or
endometrial cancer or bilateral
mastectomy
Exemestane Alternative in postmenopausal women
C35 years old with a 5-year projected
absolute BC risk C1.66 % or with LCIS
or atypical hyperplasia
Not included Not included
Should not be used for BC risk reduction
in premenopausal women
Anastrozole Not included Not included Not included
ALL Risks and benefits of each agent in the
preventive setting specifically should be
discussed prior to prescription
Engage in shared, informed decision
For women who are at increased risk for
breast cancer and at low risk for adverse
medication effects, clinicians should
offer to prescribe risk-reducing
medications, such as tamoxifen or
raloxifene
Minimum
breast
cancer
risk
required
For tamoxifen and raloxifene, a 5-year
projected absolute BC risk C1.66 % or
with LCIS
Estimated 5-year breast cancer risk of 3 %
or greater
High risk: lifetime risk of 30 % or
greater; risk of [8 % in between age
40 and 50 years
For exemestane, a 5-year projected
absolute BC risk C1.66 % or LCIS or
atypical hyperplasia
Moderate risk: lifetime risk of 17 % but
\30 %; a risk of 3–8 % between age
40 and 50 years
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comprising more than 2,500 women [9, 21]. Another
noteworthy part of this report is the exhaustive analysis of
13 risk stratification methods. On the whole, all of them
seem to offer similar results. In other words, they are
effective at the population level, with predictive capacities
over 90 %, but perform poorly in relation to concordance,
or the ability to determine individual risk (they barely
obtain areas under the curve higher than 0.6). Two recent
Spanish studies have produced similar results, also con-
firming the importance of mammographic density as a
decisive risk factor [22, 23]. It is interesting that although
the results of the MAP.3 study [24] are cited, exemestane is
not expressly included among the agents to be considered
(this also occurs with the NICE guidelines), perhaps
because of not being approved yet for the preventive
indication in the US.
With even greater diffusion, ASCO has also updated its
guidelines, for which the previous version was published in
2009. In this new edition [25], the term ‘‘chemopreven-
tion’’ has been replaced by the term ‘‘pharmacological
interventions to reduce the risk of breast cancer’’. A liter-
ature review of studies published between 2007 and 2012
included a review not only of tamoxifen and raloxifene but
also of arzoxifene, lasofoxifene, exemestane and anas-
trozole. In accordance with the available evidence, their
recommendations are much broader. Specifically, tamoxi-
fen is recommended in premenopausal women and
tamoxifen, raloxifene or exemestane in postmenopausal
women, provided that they comply with inclusion criteria
established in the clinical trials for these agents (a five-year
risk higher than 1.67 %, lobulillar hyperplasia) and always
personalising the advice, tailoring it to the risks and ben-
efits of each case. As a general rule, the preventive benefit
tends to be greater as the estimated risk increases. In this
line, the study by Freedman et al., [26] is very useful. It
stratifies the risks and benefits relative to patients’ age, and
is also adapted to take into account the STAR update [20],
which shows the greater long-term preventive capacity of
tamoxifen, and the very positive data of the Excel study
[24], showing a 65 % reduction in breast cancer incidence
compared to placebo. As we mentioned before, a truly
preventive strategy must be applicable to a large popula-
tion. Only in this way can the huge social, family, personal
and financial impact of breast cancer in western societies
be reduced.
The intention of ASCO with this update is, essentially,
to emphasize the enormous potential for health of pre-
ventive intervention in breast cancer, strengthening the
tone of the indications, which changes from one that makes
suggestions in the previous edition, to making strong rec-
ommendations in the current version, with an explicit order
to doctors to discuss these options with their potential
beneficiaries. This would perhaps manage to raise the
number of people who choose prevention, something
which has not occurred over the past 10 years [27] by a
variety of reasons, including lack of awareness and fear of
side effects.
Table 2 summarizes the main features of NICE, USPTF
and ASCO recommendations and Table 3 shows the
characteristics of the Gail 2 and Tyrer–Cuzick risk pre-
diction models.
The application of therapeutic prevention of breast
cancer in Spain
There are great opportunities in Spain to apply breast
cancer prevention and improve public health by pharma-
cological intervention. There are approximately 25,000
new cases of breast cancer each year in our country, and
over 6,000 deaths from this cause [28]. Of these cases,
approximately 14,000 occur in women over 55 years old. It
is clear that, if prevention is feasible, a large number of
high impact medical interventions could be avoided (sur-
gical interventions, chemotherapies, radiotherapy) and also
the psychological, social and work-related costs and the
long-term consequences of treatments in survivors of the
disease. In the rationale given by NICE for the recom-
mendation for the pharmacological prevention of breast
cancer, it was estimated that each case of breast cancer
prevented would cost far less than the willingness-to-pay
threshold of £20,000 per QUALY of the English NHS,
even given the conservative level of effectiveness taken
of 35 %, considered to be the same for tamoxifen and
Table 3 Methods more frequently used to identify women at
increased risk for breast cancer
Method Main features Used in
The Gail 2 model or
Breast Cancer Risk
Assessment Tool
(ref. [12]; can be
accessed at www.
cancer.gov/
bcrisktool)
It estimates the absolute
risk of developing
breast cancer in the next
5 years based on: age,
age at menarche, age of
first birth, family history
of breast cancer in first
degree relatives, number
of previous breast
biopsies, and history of
atypical hyperplasia
NSABP-1 [9]
STAR [11]
MAP.3 [24]
The Tyrer-Cuzick
model (ref. [13];
can be downloaded
at http://www.
ems-trials.org/
riskevaluator/)
It estimates the risk taking
into account family
history, hormonal and
benign disease history,
age, BMI and genetic
factors (including
BRCA) creating a single
statistical model
IBIS-II [30]
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raloxifene. In Spain, we know that efficacy data in the
Spanish cohort included by GEICAM in the MAP.3 study
are comparable to those of its whole population, in spite of
there being some differences in relation to baseline level of
estimated risk and mean age of the participants [29]. By
extrapolating the 65 % reduction in risk obtained in the
study to data for the Spanish population we can estimate
that between 7,000 and 9,000 cases of breast cancer could
be prevented in postmenopausal women per year. These
figures could be improved with the correct use of tamoxi-
fen in premenopausal women. From these data, firstly we
can infer the very great responsibility that doctors have to
convey this information to those responsible for health
policies and financing and, secondly, the urgent need to
conduct pharmacoeconomics studies to validate and sup-
port, also from an economic perspective, the value of
pharmacological prevention of breast cancer.
Preventive effect and tolerability of aromatase
inhibitors are confirmed
As mentioned before, the MAP.3 trial showed a 65 %
reduction in the incidence of invasive breast cancer in
women treated with exemestane as compared to placebo
[24]. More recently, Cuzick et al. [30] revealed the IBIS II
trial results. This study compared anastrozole and placebo
in a population of over 3,900 women with higher than
average risk of developing breast cancer. After a 5-year
follow up the authors demonstrated a 50 % reduction in the
incidence of overall and invasive breast cancer in women
taking anastrozole. This is somewhat less than the reduc-
tion observed in MAP.3 but differences in populations and
follow-up could account for this variance. A metaanalysis
of these two big trials will help define if there is some
incremental benefit in any subgroup. However, anastrozole
also showed a greater preventive efficacy than tamoxifen,
which lead Dr. Cuzick to the conclusion that aromatase
inhibitors are the primary prevention treatment of choice in
postmenopausal women. As in MAP.3 and other inter-
vention trials, prevention was seemingly restricted to
receptor positive breast cancer. Preventive drugs must have
an outstanding tolerability, in addition to efficacy and
safety, if they are to be accepted by a healthy population.
The results of the Quality of Life substudy from MAP.3
study have been published recently [31]. Exemestane had
small negative effects on vasomotor symptoms, sexual life
and pain, but only in 4 % more women than in the placebo
arm. Overall, the apparently limited impact on quality of
life makes exemestane a suitable agent for pharmacological
prevention. The placebo controlled nature of the study
gives more strength to the results.
Summary and take home messages
Pharmacologic prevention of breast cancer is a solid reality
supported by numerous well designed trials. Uptake by the
general population has been difficult due in part to the
risks, real and perceived, attributed to preventive drugs,
especially tamoxifen. Also there has not been a massive
commitment of Public Health authorities and professional
societies as the one undertaken in the past to spread the use
of blood pressure and cholesterol reducing agents. Based
on MAP.3 and IBIS II results, exemestane and anastrozole
could probably become the new standard for postmeno-
pausal women seeking a reduction in their breast cancer
risk. Tamoxifen remains the sole proven drug in pre-
menopausal women. Investigation must continue to pro-
vide new drugs with better tolerability and ability to
prevent hormone receptor negative breast cancer. Efforts
must be made to further characterise the health and eco-
nomics benefits of preventing breast cancer.
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